

## **SUPPORTING INFORMATION**

### **SI MATERIALS AND METHODS**

#### FoxP3 *ex-vivo* analysis.



The following intracellular antibody was used in accordance with manufacturers protocols: anti-FoxP3 FITC (eBioscience clone: FJK-16s) and anti-CD25 PerCP-Cy5.5 (eBioscience, clone PC61.5).

#### Anti-IL-10R mAb blockade during EAE.

Anti-IL-10R blocking mAb treatment (clone 1B1.3a; UAB hybridoma facility) was administered by i.p. injection at 250 $\mu$ g per mouse on days 0, 7, 14, and 21 post-immunization.

## SI FIGURE LEGENDS

**Figure S1: STAT4 deletion does not increase the presence or function of Tregs.** **(A)** WT and STAT4<sup>-/-</sup> mice were immunized for EAE. The frequencies and numbers of Foxp3+CD25+CD4+ T cells were determined in the dLN 10 days post immunization. **(B)** Disease severity was monitored in WT and STAT4<sup>-/-</sup> mice following EAE immunization and subsequent PBS or anti-IL-10R mAb treatment. Data represent 3 independent experiments with (A) 3-6 and (B) 2-5 mice per group. Student's t-test was performed: ns=not significant; \*=p<0.05.

**A****B**

SFigure 1